Norethindrone

• UNSPSC Description:

  Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.

• Target Antigen:

  Bacterial; Progesterone Receptor

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Vitamin D Related/Nuclear Receptor

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/norethindrone.html

• Purity:

  99.37

• Solubility:

  DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 2.7 mg/mL (ultrasonic)

• Smiles:

  C[C@@]1([C@]2(O)C#C)[C@](CC2)([H])[C@@](CCC3=CC4=O)([H])[C@]([C@@]3([H])CC4)([H])CC1

• Molecular Weight:

  298.42

• References & Citations:

  [1]Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7.|[2]Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8.|[3]Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61.|[4]Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  68-22-4